{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:44:47Z","timestamp":1777866287903,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["75A50122C00008"],"award-info":[{"award-number":["75A50122C00008"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["75A50122C00013"],"award-info":[{"award-number":["75A50122C00013"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI148450"],"award-info":[{"award-number":["UM1 AI148450"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI069412"],"award-info":[{"award-number":["UM1 AI069412"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI148576"],"award-info":[{"award-number":["UM1 AI148576"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 RR025758"],"award-info":[{"award-number":["UL1 RR025758"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068618"],"award-info":[{"award-number":["UM1 AI068618"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI069423"],"award-info":[{"award-number":["UM1 AI069423"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37AI054165"],"award-info":[{"award-number":["R37AI054165"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068635"],"award-info":[{"award-number":["UM1 AI068635"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068614"],"award-info":[{"award-number":["UM1 AI068614"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100029382","name":"HIV Vaccine Trials Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100029382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006392","name":"AIDS Clinical Trials Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128380","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T04:10:34Z","timestamp":1771733434000},"page":"128380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials"],"prefix":"10.1016","volume":"77","author":[{"given":"Aaron","family":"Hudson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Borgetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Marie","family":"Rick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew B.","family":"Laurens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel T.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia L.","family":"Gay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Goepfert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Rouphael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana M.","family":"El Sahly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenda E.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena E.","family":"Sobieszczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann R.","family":"Falsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunda","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Janes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Follmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Koup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"Priddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Shoemaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Dunkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"de Bruyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Neuzil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James G.","family":"Kublin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen R.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen L.","family":"Kotloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter B.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128380_bb0005","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.immuni.2021.07.017","article-title":"Accelerated COVID-19 vaccine development: milestones, lessons, and prospects","volume":"54","author":"Bok","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.128380_bb0010","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2026.128380_bb0015","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase","volume":"385","author":"Sahly","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128380_bb0020","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128380_bb0025","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128380_bb0030","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128380_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102168","article-title":"Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study","volume":"64","author":"Dayan","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2026.128380_bb0040","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2213-2600(23)00263-1","article-title":"Efficacy of a bivalent (D614+B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial","volume":"11","author":"Dayan","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2026.128380_bb0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.51974","article-title":"Rapid development of an integrated network infrastructure to conduct phase 3 COVID-19 vaccine trials","volume":"6","author":"Mena-Lora","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2026.128380_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104799","article-title":"Risk of COVID-19 after natural infection or vaccination","volume":"96","author":"Rick","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2026.128380_bb0055","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2117608","article-title":"Final analysis of efficacy and safety of single-dose Ad26.COV2.S","author":"Sadoff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128380_bb0060","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMp2211314","article-title":"A Covid-19 milestone attained \u2014 a correlate of protection for vaccines","volume":"387","author":"Gilbert","year":"2022","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128380_bb0065","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41591-021-01484-6","article-title":"A government-led effort to identify correlates of protection for COVID-19 vaccines","volume":"27","author":"Koup","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128380_bb0070","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1126\/science.abc5312","article-title":"A strategic approach to COVID-19 vaccine R&D","volume":"368","author":"Corey","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.128380_bb0075","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2026.128380_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1081107","article-title":"Recent updates on correlates of vaccine-induced protection","volume":"13","author":"Plotkin","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128380_bb0085","series-title":"Plotkin\u2019s Vaccines (Eighth Edition)","first-page":"45","article-title":"Chapter 4 - Correlates of Protection","author":"Plotkin","year":"2022"},{"key":"10.1016\/j.vaccine.2026.128380_bb0090","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.128380_bb0095","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41564-022-01262-1","article-title":"Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial","volume":"7","author":"Fong","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2026.128380_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00630-0","article-title":"Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine","volume":"8","author":"Benkeser","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128380_bb0105","article-title":"Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial","volume":"14","author":"Fong","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128380_bb0110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade9078","article-title":"Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial","volume":"15","author":"Benkeser","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2026.128380_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-39292-w","article-title":"Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration","volume":"14","author":"Follmann","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128380_bb0120","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijid.2023.09.012","article-title":"Stochastic interventional approach to assessing immune correlates of protection: application to the COVE messenger RNA-1273 vaccine trial","volume":"137","author":"Hejazi","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128380_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/v15102029","article-title":"Stochastic interventional vaccine efficacy and principal surrogate analyses of antibody markers as correlates of protection against symptomatic COVID-19 in the COVE mRNA-1273 trial","volume":"15","author":"Huang","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.128380_bb0130","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.vaccine.2021.12.006","article-title":"Towards a population-based threshold of protection for COVID-19 vaccines","volume":"40","author":"Goldblatt","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128380_bb0135","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128380_bb0140","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128380_bb0145","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3201\/eid2902.221422","article-title":"Correlates of protection, thresholds of protection, and Immunobridging among persons with SARS-CoV-2 infection - volume 29, number 2\u2014February 2023 - emerging infectious diseases journal - CDC","volume":"29","author":"Khoury","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128380_bb0150","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"Cromer","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.128380_bb0155","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37176-7","article-title":"Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis","volume":"14","author":"Cromer","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128380_bb0160","series-title":"NI for BS and C. Instructions for use of First WHO International Standard for anti-SARS-CoV-2 Immunoglobulin (Version 3.0, Dated 17\/12\/2020) NIBSC code: 20\/136","author":"NIBSC","year":"2026"},{"key":"10.1016\/j.vaccine.2026.128380_bb0165","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(21)00527-4","article-title":"WHO international standard for anti-SARS-CoV-2 immunoglobulin","volume":"397","author":"Kristiansen","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128380_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-03154-6","article-title":"Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation","volume":"11","author":"Huang","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128380_bb0175","doi-asserted-by":"crossref","DOI":"10.1080\/01621459.1994.10476818","article-title":"Estimation of regression coefficients when some Regressors are not always observed","volume":"89","author":"Robins","year":"1994","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.vaccine.2026.128380_bb0180","series-title":"The Highly Adaptive Lasso Estimator. 2016 IEEE Int Conf Data Sci Adv Anal (DSAA) 2016","first-page":"689","author":"Benkeser","year":"2016"},{"key":"10.1016\/j.vaccine.2026.128380_bb0185","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jama.282.8.790","article-title":"Are surrogate markers adequate to assess cardiovascular disease drugs?","volume":"282","author":"Temple","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128380_bb0190","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S1473-3099(22)00506-0","article-title":"Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Hardt","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128380_bb0195","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.15585\/mmwr.mm7149a5","article-title":"Reduced risk for Mpox after receipt of 1 or 2 doses of JYNNEOS vaccine compared with risk among unvaccinated persons \u2014 43 U.S. jurisdictions, July 31\u2013October 1, 2022","volume":"71","author":"Payne","year":"2022","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2026.128380_bb0200","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128380_bb0205","article-title":"Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128380_bb0210","author":"Prevention C for DC and"},{"key":"10.1016\/j.vaccine.2026.128380_bb0215","author":"Organization WH"},{"key":"10.1016\/j.vaccine.2026.128380_bb0220","author":"Prevention C for DC and"},{"key":"10.1016\/j.vaccine.2026.128380_bb0225","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1038\/s41591-023-02503-4","article-title":"Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial","volume":"29","author":"Branche","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128380_bb0230","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1126\/science.abg9175","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"372","author":"Stamatatos","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.128380_bb0235","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.158402","article-title":"Lower SARS-CoV-2 specific humoral immunity in people living with HIV-1 recovered from non-hospitalized COVID-19","volume":"7","author":"Schuster","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2026.128380_bb0240","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/cid\/ciae192","article-title":"COVID-19 vaccine efficacy in participants with weakened immune systems from 4 randomized controlled trials","volume":"79","author":"Sherman","year":"2024","journal-title":"Clin Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600188X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600188X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:22:56Z","timestamp":1777537376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2600188X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":48,"alternative-id":["S0264410X2600188X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128380","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128380"}}